The Mark Dredze Lab investigates topics such as natural language processing, speech, machine learning and intelligent user interfaces. Our team is currently exploring several key health information applications, including information extraction from social media and biomedical and clinical texts. Our recent research in these areas include vaccine communication during the Disneyland measles outbreak; the validity of online drug forums for estimating trends in drug use; and the use of Twitter to examine social rationales for vaccine refusal.

Research in the Mark Hughes Lab focuses on clinical and research ethics as well as clinical bioethics, ambulatory care, philosophy of medicine and palliative care.

The Mark Lazarev Lab performs clinical research on Inflammatory Bowel Disease.

Our broad research goals are to identify and validate novel molecular therapeutic targets in hematopoietic malignancies. We are interested in the identification and pre-clinical development of novel targeted therapies, and, in particular, the “translational” step of this research by using correlative studies to incorporate these novel therapies into existing treatments. Our research is of particular interest to those who wish to be involved in directly translating the results of laboratory bench work into meaningful benefits for patients. Currently, we are actively involved in the pre-clinical and clinical development of small molecule kinase inhibitors targeting the FLT3 signaling pathway in acute myeloid leukemia. We are interested in 3 compounds in particular- AC220, a FLT3/KIT inhibitor; crenolanib,a selective FLT3 inhibitor with activity against resistant point mutations; and PLX3397, another inhibitor of KIT and FLT3. The active projects in the lab include: 1) Characterization of cytotoxic responses of different hematologic malignancies to FLT3 and KIT kinase inhibition; 2) Examination of the interaction of bone marrow stroma and stroma-derived cytokines on the efficacy of these inhibitors; 3) Examination of the differential effect of FLT3 inhibition versus combined FLT3/KIT inhibition on acute myeloid leukemia and bone marrow progenitor cells; and 4) Correlative laboratory studies using blood and marrow samples from patients treated with FLT3 inhibitors, with the aim of developing predictive models for clinical response.

Research in the Mark Liu Lab explores several areas of pulmonary and respiratory medicine. Our studies primarily deal with allergic inflammation, chronic obstructive pulmonary disease (COPD) and asthma, specifically immunologic responses to asthma. We have worked to develop a microfluidic device with integrated ratiometric oxygen sensors to enable long-term control and monitoring of both chronic and cyclical hypoxia. In addition, we conduct research on topics such as the use of magnetic resonance angiography in evaluating intracranial vascular lesions and tumors as well as treatment of osteoporosis by deep sea water through bone regeneration.

Research in the Mark Sulkowski Lab focuses on hepatitis B and hepatitis C. We've conducted clinical research related to the management of viral hepatitis, including novel agents. Other studies focus on adult patients at the Johns Hopkins site of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Hepatitis B Clinical Research Network as well as the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.

The Marsh Lab studies stroke treatment, recovery and risk identification. The Marsh Lab created the Hemorrhage Risk Stratification (HeRS) score to predict hemorrhagic transformation in patients treated with anticoagulants. Currently, the Marsh Lab is using magnetoencephalography (MEG) to investigate how strokes impact higher level cognitive processes. Additional research in the lab focuses on treatment options for reversible cerebral vasoconstriction syndrome (RCVS).

The Marshall Shuler Laboratory aims to understand the means by which brain reward systems convey reward value, expectancy, quality, probability and utility, and the rules by which such activity is used to affect synaptic weight within brain networks to encode stimulus-action associations. We use an interdisciplinary approach combining multisite recordings of neural activity, targeted pharmacological manipulation, viral-mediated gene transfer and behavior to study the neural mechanisms of reward-based interval learning in the primary visual cortex.

The Cognitive Neuropsychiatric Research Laboratory (CNRLab) is part of the Division of Cognitive Neuroscience within the Department of Neurology at the Johns Hopkins University School of Medicine. Its current projects include investigating the motor system's contribution to cognitive function; HIV-related neuroplasticity and attention-to-reward as predictors of real world function; and brain function and cognition in Lyme disease.

Research in the Mary Beth Brady Lab focuses primarily on topics within the fields of anesthesiology, imaging and cardiology. Our work has explored transesophageal echocardiography simulation, echocardiography, cardiac and vascular-thoracic anesthesiology, and other areas within critical care medicine. A recent study involved obtaining 3-D images of the heart, which were then used to build computer programs to help cardiac surgeons improve their treatment of heart defects.